IL217988A0 - Pharmaceutical composition including a dha ester to be parenterally administered - Google Patents

Pharmaceutical composition including a dha ester to be parenterally administered

Info

Publication number
IL217988A0
IL217988A0 IL217988A IL21798812A IL217988A0 IL 217988 A0 IL217988 A0 IL 217988A0 IL 217988 A IL217988 A IL 217988A IL 21798812 A IL21798812 A IL 21798812A IL 217988 A0 IL217988 A0 IL 217988A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
composition including
parenterally administered
dha ester
dha
Prior art date
Application number
IL217988A
Other versions
IL217988A (en
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of IL217988A0 publication Critical patent/IL217988A0/en
Publication of IL217988A publication Critical patent/IL217988A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL217988A 2009-08-11 2012-02-07 Pharmaceutical composition including a dha ester to be administered parenterally and process for its preparation IL217988A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0955612A FR2949063B1 (en) 2009-08-11 2009-08-11 PHARMACEUTICAL COMPOSITION COMPRISING A DHA ESTER FOR PARENTERAL ADMINISTRATION
PCT/EP2010/061701 WO2011018480A1 (en) 2009-08-11 2010-08-11 Pharmaceutical composition including a dha ester to be parenterally administered

Publications (2)

Publication Number Publication Date
IL217988A0 true IL217988A0 (en) 2012-03-29
IL217988A IL217988A (en) 2016-05-31

Family

ID=42062409

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217988A IL217988A (en) 2009-08-11 2012-02-07 Pharmaceutical composition including a dha ester to be administered parenterally and process for its preparation

Country Status (23)

Country Link
US (1) US8753652B2 (en)
EP (1) EP2464335B1 (en)
JP (2) JP5847714B2 (en)
KR (1) KR101735861B1 (en)
CN (1) CN102470104B (en)
AU (1) AU2010283754B2 (en)
BR (1) BR112012003107A2 (en)
CA (1) CA2770262C (en)
ES (1) ES2566359T3 (en)
FR (1) FR2949063B1 (en)
GE (1) GEP20146088B (en)
HK (1) HK1170169A1 (en)
HU (1) HUE026807T2 (en)
IL (1) IL217988A (en)
MA (1) MA33518B1 (en)
MX (1) MX2012001718A (en)
NZ (1) NZ598082A (en)
PL (1) PL2464335T3 (en)
RU (1) RU2535029C2 (en)
TN (1) TN2012000044A1 (en)
UA (1) UA108477C2 (en)
WO (1) WO2011018480A1 (en)
ZA (1) ZA201200714B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963790B1 (en) * 2010-08-11 2012-09-28 Pf Medicament PANTHENYL DOCOSAHEXAENEOATE AND USE THEREOF IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
CN104394850A (en) * 2012-02-16 2015-03-04 布莱特赛德创新有限公司 Dietary and nutritional compositions and methods of use
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
FR2998479B1 (en) * 2012-11-27 2017-04-28 Pf Medicament USE OF A DHA ESTER FOR THE PROPHYLACTIC AND / OR CURATIVE TREATMENT OF DREPANOCYTOSIS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
DE19609477A1 (en) * 1996-03-11 1997-09-18 Basf Ag Stable aqueous solubilisates of carotenoids and vitamins
DE69734988T2 (en) * 1996-08-22 2006-09-21 Jagotec Ag PREPARATIONS CONTAINING MICROPARTICLES OF WATER-INSOLUBLE SUBSTANCES AND METHOD FOR THE PRODUCTION THEREOF
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
AU6047300A (en) * 1999-06-21 2001-01-09 Eli Lilly And Company Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistanceassociated protein-1 (mrp-1)
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
FR2805761B1 (en) * 2000-03-02 2002-08-30 Mainelab LIPID NANOCAPSULES, METHOD OF PREPARATION AND USE AS A MEDICAMENT
US20050214378A1 (en) * 2002-06-11 2005-09-29 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
KR100482269B1 (en) * 2002-10-08 2005-04-14 센츄론(주) Injectable Anaesthetic Agent Comprising 2,6-Diisopropylphenol as an Active Ingredient and Preparation Method thereof
AU2004216856A1 (en) * 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
EP1843751B1 (en) * 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
FR2902659A1 (en) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa DHA ESTER AND ITS USE IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
CN101091890A (en) 2007-07-26 2007-12-26 沈阳药科大学 Composite type emulsifier, and emulsion prepared by using the emulsifier, and preparation method
CN101259102B (en) 2008-04-17 2011-05-25 湖北福星生物科技有限公司 Micrometre level docosahexaenoic acid emulsion and preparation thereof
CN101385714B (en) * 2008-10-24 2011-07-27 苏州纳康生物科技有限公司 Preparation method of DHA lipid nano-particles

Also Published As

Publication number Publication date
WO2011018480A1 (en) 2011-02-17
KR20120047949A (en) 2012-05-14
CN102470104B (en) 2014-05-14
RU2535029C2 (en) 2014-12-10
UA108477C2 (en) 2015-05-12
AU2010283754A1 (en) 2012-03-08
BR112012003107A2 (en) 2016-02-23
IL217988A (en) 2016-05-31
FR2949063A1 (en) 2011-02-18
RU2012108049A (en) 2013-09-20
KR101735861B1 (en) 2017-05-15
NZ598082A (en) 2013-08-30
ES2566359T3 (en) 2016-04-12
TN2012000044A1 (en) 2013-09-19
EP2464335A1 (en) 2012-06-20
JP5847714B2 (en) 2016-01-27
CA2770262A1 (en) 2011-02-17
EP2464335B1 (en) 2016-01-06
US20120141563A1 (en) 2012-06-07
PL2464335T3 (en) 2016-06-30
FR2949063B1 (en) 2011-09-30
CA2770262C (en) 2016-12-06
MA33518B1 (en) 2012-08-01
JP6050440B2 (en) 2016-12-21
MX2012001718A (en) 2012-04-02
AU2010283754B2 (en) 2014-05-08
CN102470104A (en) 2012-05-23
JP2016000742A (en) 2016-01-07
JP2013501752A (en) 2013-01-17
US8753652B2 (en) 2014-06-17
HUE026807T2 (en) 2016-07-28
HK1170169A1 (en) 2013-02-22
GEP20146088B (en) 2014-05-13
ZA201200714B (en) 2013-06-26

Similar Documents

Publication Publication Date Title
HK1244827A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
ZA201105626B (en) Pharmaceutical compositions resistant to abuse
EP2253141A4 (en) Techniques to generate a visual composition for a multimedia conference event
HRP20180787T1 (en) Composition comprising a combination of dha and epa for parenteral administration prior to commencement of chemotherapy
AU2013257533A1 (en) Pharmaceutical compositions resistant to abuse
PL2429317T5 (en) Compositions rich in omega-3 fatty acids with a low content in phytanic acid
ZA201102645B (en) Method for delivering a pharmaceutical composition to patient in need thereof
IL216256A0 (en) A pharmaceutical composition
PT2349250T (en) Fatty acids for use as a medicament
EP2459189A4 (en) Fatty acids as anti-inflammatory agents
HK1246098A1 (en) Nutritional composition beneficial to small intestine
ZA201207839B (en) Pharmaceutical composition comprising a pyrimidineone derivative
ZA201304633B (en) A pharmaceutical composition
HK1170169A1 (en) Pharmaceutical composition including a dha ester to be parenterally administered dha
IL213354A0 (en) Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
GB201108383D0 (en) Improvements in and relating to pharmaceutical compositions
GB0815852D0 (en) Improvements relating to pharmaceutical compositions
IL219958A0 (en) Omega-3 fatty acid enriched meat compositions
IL206739A0 (en) Injectable pharmaceutical composition
HK1162935A1 (en) Pharmaceutical composition comprising a prostaglandin
ZA201201003B (en) A pharmaceutical composition
IL199679A0 (en) Injectable pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees